FDA extends review period for baricitinib, an investigational RA treatment
Eli Lilly announced the FDA has extended the review period for the new drug application for investigational baricitinib, a once-daily oral medication for the treatment of moderate to severe rheumatoid arthritis . The NDA for baricitinib was submitted to the FDA in Jan. 2016. January 13, 2017